A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis

Lancet Diabetes Endocrinol. 2024 Mar;12(3):209-214. doi: 10.1016/S2213-8587(23)00382-0. Epub 2024 Jan 29.

Abstract

No comprehensive classification system that guides prognosis and therapy of pituitary adenomas exists. The 2022 WHO histopathology-based classification system can only be applied to lesions that are resected, which represent few clinically significant pituitary adenomas. Many factors independent of histopathology provide mechanistic insight into causation and influence prognosis and treatment of pituitary adenomas. We propose a new approach to guide prognosis and therapy of pituitary adenomas by integrating clinical, genetic, biochemical, radiological, pathological, and molecular information for all adenomas arising from anterior pituitary cell lineages. The system uses an evidence-based scoring of risk factors to yield a cumulative score that reflects disease severity and can be used at the bedside to guide pituitary adenoma management. Once validated in prospective studies, this simple manageable classification system could provide a standardised platform for assessing disease severity, prognosis, and effects of therapy on pituitary adenomas.

Publication types

  • Review

MeSH terms

  • Adenoma* / diagnosis
  • Adenoma* / therapy
  • Humans
  • Pituitary Neoplasms* / diagnosis
  • Pituitary Neoplasms* / therapy
  • Prognosis
  • Prospective Studies
  • Risk Factors